Observing clinical outcomes in patients with cardiovascular diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study is a prospective, single center cohort analysis that registers the clinical characteristics and outcomes of patients suffering from various cardiovascular diseases, including coronary heart disease, heart failure, and hypertension. Patients will undergo multiple examinations at baseline and at one year or longer to evaluate the incidence of major cardiovascular and cerebrovascular events, heart failure readmissions, and mortality. The study aims to identify influencing factors on these outcomes over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Coronary heart disease According to coronary angiography and coronary CTA, at least one coronary artery has a degree of stenosis greater than 50%.
2. Hypertension Hypertension is defined as office systolic blood pressure is ≥ 140mmHg and/or the diastolic blood pressure is ≥ 90mmHg without the use of antihypertensive drugs.
3. Heart failure There is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure.
4. Cardiomyopathy Including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.
5. Able to sign informed consent form.

Exclusion Criteria:

1. Age\<18 years old, or\>80 years old.
2. Patients with various malignant tumors.
3. Liver dysfunction (defined as ALT or total bilirubin greater than three times the upper normal limit).
4. Renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit).
5. Those who have participated in other clinical studies within the past three months.
6. Individuals without legal capacity or with limited legal capacity.
7. Any situation where the researcher deems it unsuitable to participate in the clinical study.

Where it's running

• The First Affiliated Hospital of Xinjiang Medicial University
  Ürümqi, Xinjiang, China Recruiting

Study contacts

• Principal investigator: Xiang Xie, Prof — Xinjiang Medical University
• Study coordinator: Ying-Ying Zheng, PhD
• Email: zhengying527@163.com
• Phone: +8615214804944

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Using advanced cardiac imaging to improve treatment for patients with chest pain

  This study is testing if using advanced heart imaging techniques can help people with chest pain get better treatment and feel healthier compared to standard care.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen · NCT04709900

• Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure

  This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.

  Recruiting at 2 sites University Hospital of Cologne · Cologne and 1 other locations · NCT07721649

• Impact of a Clinical Information System on hospital outcomes for adults with chronic diseases

  This study tests whether implementing a Clinical Information System helps reduce readmissions or death within 30 days after hospital discharge for adults with chronic conditions in Alberta.

  Recruiting University of Calgary · Calgary, Alberta · NCT07609381

• Dapagliflozin to Improve Exercise and Heart Function in Fontan Patients

  This study tests whether the diabetes drug dapagliflozin can improve exercise capacity and heart function in people who had a Fontan procedure.

  Recruiting Phase 4 The University of Hong Kong · Hong Kong and 1 other locations · NCT07482943

• Vicadrostat versus spironolactone: effects on kidney function and protein markers

  This will test whether vicadrostat or spironolactone, each given with empagliflozin, changes kidney function and blood/urine protein patterns in adults with CKD and heart disease or heart failure.

  Recruiting at 2 sites Phase 2 University Medical Center Groningen · Groningen, Provincie Groningen and 1 other locations · NCT07304817

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.